02
Mon, Dec
37 New Articles

ODI Law and Wolf Theiss Advise on SHS Capital EUR 18 Million Investment in MESI Medical

ODI Law and Wolf Theiss Advise on SHS Capital EUR 18 Million Investment in MESI Medical

Slovenia
Tools
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

ODI Law has advised Slovenian diagnostic company MESI on the EUR 18 million investment received from SHS Capital's SHS VI Healthcare Investments fund. Wolf Theiss advised the investor. 

MESI Medical is a developer of medical devices committed to digitalizing healthcare at the primary level and beyond. According to an SHS press statement, MESI's core product, the mTABLET, "enabled them to introduce a new diagnostic category: predictive medical assessment. This is a combination of digital diagnostic measurements, immediate storage and availability of patient records, clinical support tools, and clinical AI recommendations on one device. Through considerable expansion over the last few years, MESI’s award-winning products are now present in more than 50 countries."

Founded in 1993, Tuebingen-based SHS is an investor specializing in the healthcare sector and aiming to build European healthcare champions. It focuses on expansion financing, shareholder changes, and succession situations.

According to SHS, the MESI investment "was provided after a strong growth and medtech entrepreneur Oliver Heine joining the company as an investor and strategic advisor in 2022. Empowered by the investment and a strong advisory board, MESI will be able to expand its sales organization and its portfolio of products and services. This includes AI-powered predictive applications and makes a real contribution to the digitization of healthcare."

ODI Law also advised MESI on Oliver Heine's original investment a year earlier (as reported by CEE Legal Matters on June 14, 2022). 

"We are thrilled that our European and global efforts have resulted in a partnership with SHS," MESI CEO Jakob Susteric commented. "The aim of our innovation is to facilitate access to relevant diagnostic data. This speeds up the diagnostic process for the patient, resulting in faster treatment and prevention of adverse events. The SHS investment will allow us to continue developing new ways for healthcare professionals to predict, diagnose, and manage various conditions with greater accuracy and efficiency."

The ODI Law team was led by partner Primoz Mikolic and included Senior Associate Klemen Erzen and Associate Eva Hafnar.

The Wolf Theiss team was led by Partner Markus Bruckmueller and included Partner Teja Balazic Jerovsek, Counsels Tjasa Lahovnik, Petra Jermol, and Ziga Dolhar, Senior Associate Neja Nastran, Associates Ana Zorn, Larisa Primozic, and Barbara Pirnat, and Legal Trainees Klara Matic and Zala Majhenic.